Agency issues alert about Thermo Fisher’s TaqPath genetic test
TUESDAY, Aug. 18, 2020 (HealthDay News) — A widely used COVID-19 test could produce inaccurate results due to issues with the equipment and software used to run the test, the U.S. Food and Drug Administration warned Monday.
The agency issued the alert about Thermo Fisher’s TaqPath genetic test.
The company is working with the FDA “to make sure that laboratory personnel understand the need for strict adherence to the instructions for use,” according to a spokeswoman for Thermo Fisher.
The FDA did not reveal how many inaccurate test results there have been.
Urine Cell-Free RNA Shows Promise as Biomarker for Bladder Cancer 
Age-, Joint-Specific Ultrasound Reference Values Set for Healthy Joints 
Retinal Imaging Can ID Atrial Fibrillation Years Before Diagnosis 
U.S. Adults May Not Understand Their Risk for Vascular Disease 
Lower Cognitive Functioning During 60s Linked to Subsequent Stroke Risk 
Polypharmacy of Prescription Medications Increased for U.S. Older Adults 
Nearly 1 in 10 Older Adults Used Cannabis in the Past Year 
Lower Vertebral Bone Mineral Density Linked to Cognitive Decline 
.jpg)